Balaxi Pharma

how big is Balaxi Pharma?

As of Jun 06, Balaxi Pharmaceuticals Ltd has a market capitalization of 286.75 Cr, with recent net sales of 292.56 Cr and net profit of 25.07 Cr over the last four quarters. Shareholder's funds are 201.36 Cr, and total assets are valued at 258.34 Cr as of Mar'24.

Market Cap: Balaxi Pharmaceuticals Ltd has a market capitalization of 286.75 Cr and is classified as a Micro Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 292.56 Cr. The sum of Net Profit for the same period is 25.07 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds amount to 201.36 Cr, and the Total Assets are valued at 258.34 Cr.

What does Balaxi Pharma do?

Balaxi Pharmaceuticals Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reported net sales of 76 Cr and a net profit of 9 Cr for the quarter ending March 2025. The company, originally founded in 1942, has a market cap of Rs 287 Cr and a P/E ratio of 11.00.

Overview: <BR>Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1942 under the name 'The Anandam Rubber Company Limited' and changed its name to 'Balaxi Ventures Limited' on August 8, 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 76 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 9 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 287 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 10.82% <BR>Price to Book: 1.22 <BR><BR>Contact Details: <BR>Address: 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road Cochin Kerala : 682035 <BR>Tel: 91-484-4032952/6596725 <BR>Email: secretarial@anandamrubberco.com <BR>Website: http://www.balaxipharma.in

When is the next results date for Balaxi Pharma?

No Upcoming Board Meetings

Has Balaxi Pharma declared dividend?

Balaxi Pharmaceuticals Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of July 1, 2022. Despite this, the company has experienced significant volatility, showing negative total returns in shorter periods, while the 5-year period reflects a positive return of 138.34%.

Balaxi Pharmaceuticals Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 01 Jul 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -38.66%, the dividend return was 0%, resulting in a total return of -38.66%.<BR><BR>For the 1-year period, the price return was -51.55%, the dividend return was 0%, leading to a total return of -51.55%.<BR><BR>Over the 2-year period, the price return was -51.61%, with a dividend return of 0%, culminating in a total return of -51.61%.<BR><BR>In the 3-year period, the price return was -37.85%, the dividend return was 0.68%, resulting in a total return of -37.17%.<BR><BR>For the 4-year period, the price return was -57.93%, the dividend return was 0.43%, leading to a total return of -57.5%.<BR><BR>In the 5-year period, the price return was 136.37%, with a dividend return of 1.97%, culminating in a total return of 138.34%.<BR><BR>Overall, Balaxi Pharmaceuticals Ltd has declared a dividend, but the total returns over the various periods indicate significant volatility, with negative returns dominating in the shorter time frames, while the 5-year period shows a substantial positive return.

Who are the peers of the Balaxi Pharma?

Balaxi Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma and Cipla show excellent management and growth, while Divi's Lab has the highest 1-year return at 51.96%, compared to Balaxi Pharma's 0.00%.

Peers: The peers of Balaxi Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and Alpa Laboratorie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, while Below Average management risk is found at Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Kimia Bioscien., Pharmaids Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Alpa Laboratorie, while Good capital structure is found at Torrent Pharma, Natural Capsules, Coral Labs., and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Natural Capsules has the lowest at -20.72%. Balaxi Pharma's 1-year return is 0.00%, which is lower than both of these peers. Additionally, the six-month return is negative for Natural Capsules, Coral Labs., and Pharmaids Pharma.

What is the technical trend for Balaxi Pharma?

As of April 21, 2025, Balaxi Pharma's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and KST indicators, despite some divergence in the RSI and mildly bearish Bollinger Bands.

As of 21 April 2025, the technical trend for Balaxi Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, indicating some divergence. Bollinger Bands are mildly bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. Overall, the bearish signals dominate the current technical outlook.

Who are in the management team of Balaxi Pharma?

As of March 2023, the management team of Balaxi Pharma includes Ashish Maheshwari (Chairman/Executive Director), Minoshi Maheshwari (Non-Executive Director), and five Independent Non-Executive Directors: Kunal M Bhakta, Gandhi Gamji, M. Srinivas Rao, and Purnima Singh Kamble.

As of March 2023, the management team of Balaxi Pharma includes the following individuals:<BR><BR>1. Ashish Maheshwari - Chairman / Executive Director<BR>2. Minoshi Maheshwari - Non Executive Director<BR>3. Kunal M Bhakta - Independent Non Executive Director<BR>4. Gandhi Gamji - Independent Non Executive Director<BR>5. M. Srinivas Rao - Independent Non Executive Director<BR>6. Purnima Singh Kamble - Independent Non Executive Director

Who are the top shareholders of the Balaxi Pharma?

The top shareholders of Balaxi Pharma include Balaxi Overseas Private Limited with 63.4%, foreign institutional investors holding 16.02%, and Unico Global Opportunities Fund Limited as the largest public shareholder at 8.29%. Individual investors own 9.82%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Balaxi Pharma include the promoters, with Balaxi Overseas Private Limited holding the largest share at 63.4%. Additionally, foreign institutional investors (FIIs) collectively hold 16.02%, with three FIIs involved. The highest public shareholder is Unico Global Opportunities Fund Limited, which owns 8.29%. Individual investors account for 9.82% of the company's shares. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024. The company's total assets increased to 310.34 Cr in March 2025, up from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr from 258.34 Cr. Cash flow from operating activities turned negative at -35.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2024, indicating challenges in cash generation. Overall, Balaxi Pharma's financial performance reflects volatility with a recent trend of declining profits despite increased sales.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.

Is Balaxi Pharma overvalued or undervalued?

As of November 27, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 14.36, significantly lower than its peers like Bajaj Finance and Bajaj Finserv, despite a 53.22% decline in stock performance over the past year.

As of 27 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.36, an EV to EBIT of 11.30, and an EV to EBITDA of 10.33. These ratios suggest that Balaxi Pharma is trading at a lower valuation compared to its peers, particularly when compared to Bajaj Finance, which has a PE ratio of 35.15, and Bajaj Finserv, with a PE ratio of 34.78.<BR><BR>In the context of its industry, Balaxi Pharma's Price to Book Value stands at 0.87, which further reinforces its undervaluation relative to competitors like Life Insurance, which has a PE ratio of 11.14 and an EV to EBITDA of 9.18. Despite recent stock performance showing a decline of 53.22% over the past year compared to a 7.99% increase in the Sensex, the current valuation metrics position Balaxi Pharma as an attractive investment opportunity moving forward.

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

Balaxi Pharmaceuticals Ltd's latest Q3 FY26 results are concerning, showing a 94.22% decline in net profit year-on-year and a drop in profit margins, indicating significant profitability and operational challenges. Despite some sequential improvements, the overall performance is negative.

Balaxi Pharmaceuticals Ltd's latest results for Q3 FY26 are concerning and can be characterized as bad. The company reported a net profit of ₹0.31 crores, which represents a staggering decline of 94.22% year-on-year. Revenue also saw a slight decrease of 1.02%, coming in at ₹72.54 crores compared to ₹73.29 crores in the same quarter last year.<BR><BR>The profitability metrics indicate significant challenges. The profit after tax (PAT) margin has dropped to just 0.43%, down from 7.31% a year ago, highlighting a severe erosion of profitability. Additionally, the operating margin has decreased to 4.26% from 5.44% in the previous year, suggesting deteriorating operational efficiency.<BR><BR>While there was some sequential improvement—net profit increased by 47.62% and revenue grew by 29.12% compared to the previous quarter—this does not offset the overall negative trend. The extraordinary tax burden of 80.75% has further exacerbated the situation, significantly impacting post-tax earnings.<BR><BR>Overall, the results reflect a company grappling with fundamental profitability issues, operational inefficiencies, and a concerning tax situation, making the latest performance decidedly negative.

Should I buy, sell or hold Balaxi Pharmaceuticals Ltd?

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 17-Mar, Balaxi Pharmaceuticals Ltd's stock price is Rs. 17.70, reflecting a slight increase today, but it has experienced significant declines of 11.76% over the past week and 74.26% over the past year. The stock remains below its moving averages, indicating a bearish trend despite increased investor participation.

As of 17-Mar, Balaxi Pharmaceuticals Ltd is experiencing a slight rise in its stock price, currently at Rs. 17.70, with a change of 0.03 (0.17%) upward. However, this increase comes against a backdrop of significant declines in the stock's performance over various time periods. The stock has fallen by 11.76% over the past week, 15.11% over the past month, and a staggering 34.13% year-to-date. Over the past year, the stock has decreased by 74.26%, and over three years, it has dropped by 83.79%.<BR><BR>Today's trading session has seen the stock hit a new 52-week low of Rs. 17.05 earlier in the day, indicating ongoing struggles. Furthermore, Balaxi Pharmaceuticals is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend.<BR><BR>Despite the slight uptick in price today, the stock has underperformed its sector by 0.63%. However, there has been a notable increase in investor participation, with delivery volume rising by 111.7% compared to the 5-day average, which may indicate some renewed interest from investors. Nevertheless, the overall liquidity remains adequate for trading, as the stock is liquid enough for a trade size of Rs 0 crore based on 2% of the 5-day average traded value.<BR><BR>In summary, while there is a minor increase in the stock price today, the overall trend remains negative, with significant declines over longer periods and underperformance relative to the sector.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 18-Mar, Balaxi Pharmaceuticals Ltd's stock price is Rs 17.94, reflecting a slight increase but a significant long-term decline of -72.66% over the past year. The stock is near its 52-week low and below key moving averages, indicating a persistent downward trend and waning investor interest.

As of 18-Mar, Balaxi Pharmaceuticals Ltd is experiencing a slight rise in its stock price, currently at Rs 17.94, reflecting an increase of 0.24 (1.36%). However, this upward movement occurs against a backdrop of significant long-term declines in the stock's performance. Over the past year, the stock has generated a return of -72.66%, indicating substantial underperformance compared to the benchmark Sensex, which has risen by 4.13% during the same period. <BR><BR>The stock is currently trading close to its 52-week low, just 4.96% above Rs 17.05, and it is below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a persistent downward trend in the stock's price. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 33.68% against the 5-day average, indicating waning interest from investors.<BR><BR>Institutional investors have also reduced their stakes by 1.75% in the last quarter, which may further contribute to the stock's struggles, as these investors typically have more resources to analyze company fundamentals. The company's weak long-term fundamentals are highlighted by a -14.09% CAGR growth in operating profits and a significant decline in profits by -64.1% over the past year. <BR><BR>While the stock is trading at a discount compared to its peers and has a very attractive valuation with a Price to Book Value of 0.4, these factors have not been sufficient to counteract the overall negative sentiment and performance trends surrounding Balaxi Pharmaceuticals Ltd.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 19-Mar, Balaxi Pharmaceuticals Ltd's stock price is slightly up at 18.02, but it has a troubling annual return of -74.61% and shows weak long-term fundamentals, indicating ongoing challenges despite a minor daily gain. Investor participation is declining, and institutional confidence is low, reflecting significant pressure on the stock.

As of 19-Mar, Balaxi Pharmaceuticals Ltd is experiencing a slight rise in its stock price, currently at 18.02, with a change of 0.08 (0.45%) upwards. However, despite this minor increase, the overall performance of the stock indicates significant challenges. Over the past year, the stock has generated a return of -74.61%, which highlights a consistent underperformance against the benchmark, as it has also underperformed the BSE500 in each of the last three annual periods.<BR><BR>The stock's recent performance shows that it has outperformed its sector by 4.29% today, but it is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a lack of momentum in the stock's price recovery. Additionally, there has been a decline in investor participation, with delivery volume falling by 3.57% against the 5-day average, indicating reduced interest from investors.<BR><BR>Furthermore, the company faces weak long-term fundamental strength, evidenced by a -14.09% CAGR growth in operating profits and a significant drop in profits by -64.1% over the past year. Institutional investors have also decreased their stake by -1.75% in the previous quarter, which reflects a lack of confidence in the company's future prospects. Overall, while there is a slight uptick in the stock price today, the broader context of declining performance metrics and investor participation suggests that the stock remains under significant pressure.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 20-Mar, Balaxi Pharmaceuticals Ltd's stock price is Rs 17.65, reflecting a 2.05% decrease and significant underperformance with a year-to-date decline of 34.31%. The stock is near its 52-week low and trading below all key moving averages, indicating a bearish trend.

As of 20-Mar, Balaxi Pharmaceuticals Ltd's stock price is falling, currently at Rs 17.65, which reflects a decrease of Rs 0.37 or 2.05%. The stock has shown significant underperformance over various periods, with a year-to-date decline of 34.31% compared to a 11.54% drop in the Sensex. Over the past year, the stock has plummeted by 74.63%, while the benchmark index has remained relatively stable with a decrease of only 0.33%.<BR><BR>Today's performance indicates that the stock is close to its 52-week low, being only 3.4% away from Rs 17.05. Additionally, it has underperformed its sector by 1.48%. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 32.33% compared to the 5-day average. These factors collectively contribute to the ongoing decline in Balaxi Pharmaceuticals Ltd's stock price.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 23-Mar, Balaxi Pharmaceuticals Ltd's stock price is Rs 17.27, down 2.15%, reflecting a significant decline of 75.05% over the past year. Despite an attractive valuation, negative sentiment persists due to consistent underperformance and declining profits.

As of 23-Mar, Balaxi Pharmaceuticals Ltd's stock price is falling, currently at Rs 17.27, reflecting a decrease of Rs 0.38 or 2.15%. This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, with a staggering 75.05% drop over the past year and an 84.18% decrease over the last three years compared to the benchmark. <BR><BR>The stock is also trading lower than its moving averages across multiple periods, indicating a bearish trend. Additionally, while there has been a rise in investor participation, with delivery volume increasing by 356.03% on March 20, this has not translated into a positive price movement. The company's fundamentals show weak long-term strength, highlighted by a -14.09% compound annual growth rate in operating profits and a significant drop in institutional investor participation, which decreased by 1.75% in the last quarter. <BR><BR>Despite a very attractive valuation with a low price-to-book ratio and trading at a discount compared to peers, the overall sentiment remains negative due to consistent underperformance and declining profits, which have fallen by 64.1% over the past year. Thus, these factors contribute to the stock's current downward trajectory.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 24-Mar, Balaxi Pharmaceuticals Ltd's stock price has risen to 18.06, driven by increased investor participation and sector outperformance. However, the company faces significant long-term challenges, including a -74.39% return over the past year and declining profits.

As of 24-Mar, Balaxi Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 18.06, with a change of 0.79 (4.57%) upwards. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 2.25% today, indicating a positive shift in market sentiment. Additionally, there has been a significant rise in investor participation, with a delivery volume of 5.86 lacs on 23 March, which represents a 381.67% increase compared to the 5-day average delivery volume. This heightened activity suggests renewed interest from investors.<BR><BR>Despite these positive movements, it is important to consider the broader context of the stock's performance. Over the past year, Balaxi Pharmaceuticals has generated a return of -74.39%, and its profits have decreased by -64.1%. Furthermore, the stock has consistently underperformed against benchmarks, including a -83.49% return over the last three years. The long-term fundamental strength appears weak, with a -14.09% CAGR growth in operating profits and a decrease in institutional investor participation, which has fallen by -1.75% in the previous quarter.<BR><BR>In summary, while the stock is currently rising due to increased investor participation and sector outperformance, it faces significant challenges and a history of underperformance that may affect its long-term outlook.

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 25-Mar, Balaxi Pharmaceuticals Ltd's stock price is Rs 17.74, reflecting a 1.77% decline and a significant year-to-date drop of 33.98%. The stock is near its 52-week low and continues to underperform against its sector and major indices.

As of 25-Mar, Balaxi Pharmaceuticals Ltd's stock price is falling, currently at Rs 17.74, which reflects a decrease of Rs 0.32 or 1.77%. The stock has underperformed significantly over various time periods, with a year-to-date decline of 33.98% compared to a 10.80% drop in the Sensex. Over the past year, the stock has plummeted by 73.98%, while the benchmark index has only decreased by 1.53%. <BR><BR>Additionally, the stock is close to its 52-week low, being only 3.89% away from Rs 17.05. Today's performance shows that it has underperformed its sector by 4.69%. Although there has been a rise in investor participation, with a delivery volume increase of 187% compared to the 5-day average, the overall trend remains negative as the stock is lower than the 20-day, 50-day, 100-day, and 200-day moving averages. These factors collectively indicate that the stock is experiencing a downward trend.

Which are the latest news on Balaxi Pharma?